Ilyang Pharm’s ‘Prion Treatment Development’ selection as study supported by MOHW

Published: 2018-01-19 16:26:00
Updated: 2018-01-19 10:02:16

The Ilyang Pharm’s(CEO Dong-Yeon Kim) development of prion treatment has recently been selected as the ‘Development of Technology to Overcome Diseases Transmitted Cross-species to Humans’ by the Ministry of Health and Welfare(MOHW).

Ilyang Pharm has conducted a broad-scale research with the most...


- Email service daily and homepage access.
  1. $300 per month. ($3,240 per year)
  2. 5 Email holders per each company.
  3. Anual contract base.

Original Korean

Most Read News

Address: 295-1, Chungpa-Ro, Yongsan-Gu, Korea
Phone: 02-3270-0114 | Fax: 02-3270-0129 | Email:

Copyright © Yakup Shinmoon, Inc. All Rights Reserved.